Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared With Chemotherapy in Previously Treated Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States
doi 10.1097/jto.0000000000000318
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P2.13-04 Outcomes of ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Crizotinib: A Multicenter Cohort Retrospective Study.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Case Report of an EML4-ALK-positive Elderly Non-Small Cell Lung Cancer Patient With a Poor PS Successfully Treated With Crizotinib

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2013English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

P3.15-31 Better Clinical Outcomes and Resistance Mechanisms of Crizotinib in ALK-Positive Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy